Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label Arikace in cystic fibrosis with chronic Pseudomonas aeruginosa infection
2011-000443-24Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of amikacin liposome inhalation suspension in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection, sponsored by Insmed Incorporated. Primary endpoint: Treatment emergent adverse events. Started May 2011; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on 2011-000443-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000443-24.